1 – 7 of 7
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2013
-
Mark
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2008
-
Mark
Long Term Efficacy And Tolerability Of Anagrelide In Myeloproliferative Disorders
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0746-0746(
- Contribution to journal › Published meeting abstract
- 2004
-
Mark
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders
(
- Contribution to journal › Article
- 2003
-
Mark
More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML
(
- Contribution to journal › Article